Voyager Therapeutics, Inc.
NASDAQ:VYGRBiotechnology
+$0.09 today
- Market cap
- $94.59M
- Beta
- 1.25
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$1.96
Volume 0.99M
Average 0.54M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Voyager Therapeutics, Inc.
NASDAQ:VYGR
Intrinsic Alpha fair value
Locked
Current Price
$1.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | -0.4% | +15.1% (5yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at -0.4% over three years. Forward estimates point to Revenue at +15.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Achieve Life Sciences, Inc. NASDAQ:ACHV | $697.68M | $6.78 | Not rated | -5.1 | +56.58% |
Atea Pharmaceuticals, Inc. NASDAQ:AVIR | $345.31M | $4.30 | Not rated | -2.0 | +29.84% |
Sagimet Biosciences Inc. NASDAQ:SGMT | $332.99M | $10.22 | Not rated | -5.0 | +25.96% |
Enanta Pharmaceuticals, Inc. NASDAQ:ENTA | $320.09M | $10.99 | Not rated | -4.3 | -29.69% |
Allogene Therapeutics, Inc. NASDAQ:ALLO | $290.58M | $0.84 | Not rated | -2.7 | -43.20% |
Vanda Pharmaceuticals Inc. NASDAQ:VNDA | $241.27M | $3.99 | Not rated | -1.4 | -28.79% |
Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT | $240.96M | $8.36 | Not rated | -2.7 | +20.39% |
Entrada Therapeutics, Inc. NASDAQ:TRDA | $199.28M | $5.09 | Not rated | -1.7 | -43.76% |
Humacyte, Inc. NASDAQ:HUMA | $155.12M | $0.56 | Not rated | -1.9 | -58.25% |
Pyxis Oncology, Inc. NASDAQ:PYXS | $100.10M | $1.58 | Not rated | -1.6 | -69.49% |
Continue the stock analysis
Jump to another research area for this company.